Agilent rises on $950 million deal to buy cancer diagnostics firm Biocare
09/03/2026 14:04
** Shares of medical equipment maker Agilent Technologies A.N rise 1% to $115 ** Co says it will buy privately held clinical pathology firm Biocare Medical for $950 million in cash ** Biocare Medical's pipeline includes integrated tissue‑diagnostic tools for cancer and infectious diseases; its website lists government and military labs among its customers ** Agilent says deal will boost revenue growth and profit margins in the first year and lift its share of sales from consumables and services ** Adds acquisition strengthens its position in immunohistochemistry, a key cancer diagnostics method that uses antibodies to identify abnormal cells ** Deal expected to close by end of Q4 2026, pending regulatory clearance ** Shares rose ~1% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))